Hyperglykæmi hos personer med diabetes og kronisk nyresygdom

Julie Maria Bøggild Brøsen; Tobias Bomholt; Rikke Borg; Frederik Persson; Ulrik Pedersen-Bjergaard

doi:10.61409/V01240051

Hyperglykæmi hos personer med diabetes og kronisk nyresygdom

Julie Maria Bøggild Brøsen^*, Tobias Bomholt, Rikke Borg, Frederik Persson, Ulrik Pedersen-Bjergaard

^*Corresponding author af dette arbejde

2 Citationer (Scopus)

Abstract

Assessment and treatment of hyperglycaemia in people with diabetes and chronic kidney disease (CKD) are challenging. In advanced CKD HbA1c can be unreliable, and treatment adjustments should be supported by other glucose measurements (e.g., continuous glucose monitoring (CGM) or blood glucose measurements). Glucose-lowering treatments should be evaluated based on CKD and an individualised assessment of risk factors especially hypoglycaemia. This review aims at providing an overview of the options for glycaemic monitoring and glucose-lowering treatments in people with diabetes and CKD.

Bidragets oversatte titel	Hyperglycaemia in people with diabetes and chronic kidney disease
Originalsprog	Dansk
Artikelnummer	V01240051
Tidsskrift	Ugeskrift for Laeger
Vol/bind	186
Udgave nummer	20
ISSN	0041-5782
DOI	https://doi.org/10.61409/V01240051
Status	Udgivet - 13 maj 2024

Emneord

Humans
Renal Insufficiency, Chronic/complications
Hyperglycemia/complications
Hypoglycemic Agents/therapeutic use
Blood Glucose/metabolism
Blood Glucose Self-Monitoring
Glycated Hemoglobin/analysis
Diabetes Mellitus, Type 2/complications
Diabetes Mellitus/blood
Diabetic Nephropathies/complications
Risk Factors

Adgang til dokumentet

10.61409/V01240051

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{43549c8aaaf84166a1cba18212b172dc,

title = "Hyperglyk{\ae}mi hos personer med diabetes og kronisk nyresygdom",

abstract = "Assessment and treatment of hyperglycaemia in people with diabetes and chronic kidney disease (CKD) are challenging. In advanced CKD HbA1c can be unreliable, and treatment adjustments should be supported by other glucose measurements (e.g., continuous glucose monitoring (CGM) or blood glucose measurements). Glucose-lowering treatments should be evaluated based on CKD and an individualised assessment of risk factors especially hypoglycaemia. This review aims at providing an overview of the options for glycaemic monitoring and glucose-lowering treatments in people with diabetes and CKD.",

keywords = "Humans, Renal Insufficiency, Chronic/complications, Hyperglycemia/complications, Hypoglycemic Agents/therapeutic use, Blood Glucose/metabolism, Blood Glucose Self-Monitoring, Glycated Hemoglobin/analysis, Diabetes Mellitus, Type 2/complications, Diabetes Mellitus/blood, Diabetic Nephropathies/complications, Risk Factors",

author = "Br{\o}sen, {Julie Maria B{\o}ggild} and Tobias Bomholt and Rikke Borg and Frederik Persson and Ulrik Pedersen-Bjergaard",

note = "Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.",

year = "2024",

month = may,

day = "13",

doi = "10.61409/V01240051",

language = "Dansk",

volume = "186",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "20",

}

TY - JOUR

T1 - Hyperglykæmi hos personer med diabetes og kronisk nyresygdom

AU - Brøsen, Julie Maria Bøggild

AU - Bomholt, Tobias

AU - Borg, Rikke

AU - Persson, Frederik

AU - Pedersen-Bjergaard, Ulrik

N1 - Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.

PY - 2024/5/13

Y1 - 2024/5/13

N2 - Assessment and treatment of hyperglycaemia in people with diabetes and chronic kidney disease (CKD) are challenging. In advanced CKD HbA1c can be unreliable, and treatment adjustments should be supported by other glucose measurements (e.g., continuous glucose monitoring (CGM) or blood glucose measurements). Glucose-lowering treatments should be evaluated based on CKD and an individualised assessment of risk factors especially hypoglycaemia. This review aims at providing an overview of the options for glycaemic monitoring and glucose-lowering treatments in people with diabetes and CKD.

AB - Assessment and treatment of hyperglycaemia in people with diabetes and chronic kidney disease (CKD) are challenging. In advanced CKD HbA1c can be unreliable, and treatment adjustments should be supported by other glucose measurements (e.g., continuous glucose monitoring (CGM) or blood glucose measurements). Glucose-lowering treatments should be evaluated based on CKD and an individualised assessment of risk factors especially hypoglycaemia. This review aims at providing an overview of the options for glycaemic monitoring and glucose-lowering treatments in people with diabetes and CKD.

KW - Humans

KW - Renal Insufficiency, Chronic/complications

KW - Hyperglycemia/complications

KW - Hypoglycemic Agents/therapeutic use

KW - Blood Glucose/metabolism

KW - Blood Glucose Self-Monitoring

KW - Glycated Hemoglobin/analysis

KW - Diabetes Mellitus, Type 2/complications

KW - Diabetes Mellitus/blood

KW - Diabetic Nephropathies/complications

KW - Risk Factors

UR - http://www.scopus.com/inward/record.url?scp=85194817069&partnerID=8YFLogxK

U2 - 10.61409/V01240051

DO - 10.61409/V01240051

M3 - Tidsskriftartikel

C2 - 38808757

SN - 0041-5782

VL - 186

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 20

M1 - V01240051

ER -

Hyperglykæmi hos personer med diabetes og kronisk nyresygdom

Abstract

Emneord

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater